top of page

Aprea announces efficacy and safety data for APR-246 in ovarian cancer

Aprea has presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page